APA (7th ed.) Citation

Li, M., Zhong, X., Zhang, C., Luo, H., Luo, L., Huang, Y., & Jiang, L. (2024). Cost-effectiveness of acalabrutinib monotherapy or with obinutuzumab versus chemoimmunotherapy for untreated chronic lymphocytic leukemia in China. Therapeutic Advances in Hematology, 15, . https://doi.org/10.1177/20406207241295559

Chicago Style (17th ed.) Citation

Li, Mengya, Xiaoyan Zhong, Chengbin Zhang, Hongli Luo, Li Luo, Yilan Huang, and Longyang Jiang. "Cost-effectiveness of Acalabrutinib Monotherapy or with Obinutuzumab Versus Chemoimmunotherapy for Untreated Chronic Lymphocytic Leukemia in China." Therapeutic Advances in Hematology 15 (2024). https://doi.org/10.1177/20406207241295559.

MLA (9th ed.) Citation

Li, Mengya, et al. "Cost-effectiveness of Acalabrutinib Monotherapy or with Obinutuzumab Versus Chemoimmunotherapy for Untreated Chronic Lymphocytic Leukemia in China." Therapeutic Advances in Hematology, vol. 15, 2024, https://doi.org/10.1177/20406207241295559.